Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28710888 | 0.81 | MEN1 (0.50) | CYP3A4CYP2C19SMN1; SMN2HPGDLMNA | |
| SCHEMBL3341865 | 0.79 | MEN1 (0.48) | CYP3A4CYP2C19SMN1; SMN2HPGDLMNA | |
| SCHEMBL11941497 | 0.75 | MEN1 (0.46) | CYP3A4CYP2C19LMNAKMT2AMEN1 | |
| SCHEMBL10690351 | 0.75 | KMT2A (0.46) | SMN1; SMN2HPGDLMNAKMT2AMEN1 | |
| SCHEMBL11941449 | 0.75 | MEN1 (0.46) | CYP3A4CYP2C19LMNAKMT2AMEN1 | |
| SCHEMBL5934973 | 0.75 | CYP3A4 (0.44) | CYP3A4CYP2C19SMN1; SMN2HPGDLMNA | |
| SCHEMBL28857096 | 0.73 | MEN1 (0.48) | CYP3A4CYP2C19SMN1; SMN2HPGDLMNA | |
| SCHEMBL5934352 | 0.70 | — | — | |
| SCHEMBL6736653 | 0.70 | MEN1 (0.41) | CYP3A4LMNAKMT2AMEN1GAA | |
| SCHEMBL29751383 | 0.70 | LMNA (0.39) | CYP3A4CYP2C19LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358896-B2 | LRRK2 inhibitors and methods of making and using thereof | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-3953348-B1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20220220094-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-07-14 | — | — | US | disclosed |
| US-20220153728-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-19 | — | — | US | disclosed |
| EP-3953348-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-113939294-A | Compounds, compositions and methods | 戴纳立制药公司 | 2022-01-14 | — | — | CN | disclosed |
| WO-2020210684-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20200157081-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2020-05-21 | — | — | US | disclosed |
| US-7105509-B2 | Benzodiazepine derivatives as APP modulators | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20040260097-A1 | Insecticidal and acaricidal 3-substituted pyrazoles | BASF AKTIENGESELLSCHAFT (DE) | 2004-12-23 | — | — | US | disclosed |
| EP-1432688-A1 | INSECTICIDAL AND ACARICIDAL 3-SUBSTITUTED PYRAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2004-06-30 | — | — | EP | disclosed |
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | MERCK SHARPE & DOHME LIMITED (GB) | 2004-04-29 | — | — | US | disclosed |
| WO-2003029222-A1 | INSECTICIDAL AND ACARICIDAL 3-SUBSTITUTED PYRAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2003-04-10 | — | — | WO | disclosed |
| EP-1294702-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001090084-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220094-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | LRRK2, GSK3B, SNCA | CYP3A4 2756/4885CYP2C19 2208/4885SMN1; SMN2 63/4885 |
| US-20200157081-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | LRRK2, SNCA, GSK3B | CYP3A4 3266/4885CYP2C19 2838/4885SMN1; SMN2 95/4885 |
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | BACE1, PSEN1, APP | CYP3A4 212/4885CYP2C19 385/4885SMN1; SMN2 2060/4885 |
| US-20220153728-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | LRRK2, SNCA, GSK3B | CYP3A4 3266/4885CYP2C19 2838/4885SMN1; SMN2 95/4885 |
| US-20040260097-A1 | Insecticidal and acaricidal 3-substituted pyrazoles | SCN3A, KCNH1, HCN3 | CYP3A4 1491/4885CYP2C19 3017/4885SMN1; SMN2 1603/4885 |
| US-12358896-B2 | LRRK2 inhibitors and methods of making and using thereof | LRRK2, PARK7, GSK3B | CYP3A4 4037/4885CYP2C19 3095/4885SMN1; SMN2 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.